Effect of Intra-Operative Hyperglycemia and Insulin Treatment on Post-Operative Neutrophil Counts: a Retrospective Observational Study
Xiaochen Zhang,Yuelun Zhang,Le Shen,Yuguang Huang
DOI: https://doi.org/10.1097/cm9.0000000000002299
2023-01-01
Abstract:To the Editor: Peri-operative hyperglycemia in patients with or without diabetes is associated with a higher incidence of post-operative complications.[1] In China, more than 130 million people have been diagnosed with diabetes, and more than one-third of the total population has prediabetes. Hyperglycemia in hospitalized patients is common, and the peri-operative hyperglycemia rate varies from 30% to 40% in different studies.[2] Controlling peri-operative blood glucose is conducive to a better outcome of surgery and this has become a broad consensus; the awareness of a need for blood glucose control is continuously increasing among surgeons. It has been reported that the immune cell composition following hyperglycemia differs in both diabetic and non-diabetic patients, as compared to other patients.[3] To study the impact of intra-operative blood glucose management, an observational study was performed on intra-operative hyperglycemia patients to compare the outcomes of patients who received insulin treatment and those who did not. Patients who underwent non-cardiac scheduled surgeries from January 2020 to July 2021 at Peking Union Medical College Hospital (PUMCH) were included. The demographic information, peri-operative blood glucose level, and major laboratory tests of the patients were collected. General, hepatic, thoracic, orthopedic, urological, vascular, and gynecological surgeries were included in this cohort. Hyperglycemia was defined as any intra-operative glucose ≥10 mmol/L. The ethics of this study were reviewed and approved by the Ethics Committee of PUMCH (No. S-K1782). There were a total of 13,206 arterial blood gas (ABG) records from January 1, 2020 to July 31, 2021, from 3103 patients. Among these records, 903 patients (29.10%) suffered from intra-operative hyperglycemia. Among these hyperglycemia patients, 472 patients underwent cardiac surgeries, 101 patients underwent emergency surgeries, and 216 patients underwent scheduled operations. There were 114 patients who lacked intact ABG records. Among these 216 patients, 90 patients were previously diagnosed with diabetes, 16 patients did not have a blood test ≥2 times, and 46 patients had an intra-operative blood glucose ≥14 mmol/L, which could be defined as severe hyperglycemia. The inclusion and exclusion criteria are shown in [Supplementary Figure 1, https://links.lww.com/CM9/B391]. Intra-operative insulin administration was collected from the patients’ medical records. Among these patients, 39 received insulin treatment. A total of 43.18% (19/44) of the patients suffering from severe hyperglycemia received insulin administration. According to the surgery type, 22.50% (45/200) of these patients underwent general surgery, and 25.00% (11/44) of patients who underwent urology surgery received insulin administration. The clinical and demographic characteristics of the cohort are described in [Supplementary Table 1, https://links.lww.com/CM9/B391]. Post-operative laboratory tests of the patients were analyzed. Patients without insulin treatment had significantly higher neutrophil counts than the insulin-treated group on the morning of post-operative day 1 (POD1) ([10.13 ± 3.45] ×109/L vs. [8.11 ± 2.72] ×109/L, P <0.01). This finding is identical to the neutrophil counts immediately after surgery ([11.44 ± 5.24] ×109/L vs. [8.53 ± 3.24] ×109/L, P <0.01). White blood cell (WBC) counts were analyzed in the same way, and the conclusion was the same as that for neutrophils both on the morning of POD1 and immediately after surgery [Figure 1A]. Regarding the neutrophil percentage, there was a significantly lower percentage immediately after surgery (86.77% ± 6.18% vs. 89.62% ± 5.51%, P = 0.02). The percentage was still lower on the morning of POD1 but did not reach significance (82.70 ± 8.41 vs. 84.77 ± 6.32, P = 0.18). Considering that the absolute number of cell counts may not represent the clinical significance very well, post-operative laboratory test results were also analyzed to whether they were in the normal range. The percentage of abnormal neutrophil counts was significantly different between the insulin-treated group and the group without treatment both on the morning of POD1 (52.78% [19/36] vs. 79.26% [130/164], P <0.01) and immediately after surgery (51.43% [19/35] vs. 78.05% [128/164], P <0.01). The percentage of abnormal WBC counts was only significant on the morning of POD1 (37.14% [13/35] vs. 73.78% [121/164], P <0.01). The abnormal range of neutrophil counts on the morning of POD1 was still significant between insulin-treated and untreated patients (OR = 0.22, P <0.01) after multivariable analyses using binary logistic regression analysis, which included sex, age, American Society of Anesthesiologists (ASA) grading diabetes, type, and time of surgery [Supplementary Table 2, https://links.lww.com/CM9/B391]. The WBC count abnormal range on the morning of POD1 (OR = 0.17, P <0.01) showed a similar trend [Supplementary Table 3, https://links.lww.com/CM9/B391].Figure 1: The postsurgical laboratory tests (A), hospitalization demographics (B), and short-term adverse events (C) of intraoperative hyperglycemia patients treated with or without insulin.Creatinine and alanine aminotransferase were analyzed to represent renal and liver function. For these two indicators, the difference was not significant at either time point. Although patients from the insulin-treated group had longer hospitalization days, post-surgery hospitalization days, ICU length of stay, and post-surgery ventilation hours, these outcome measures were not significantly different from the group without insulin treatment [Figure 1B]. Finally, the short-term adverse events of these patients were analysed: 2.78% (1/36) of the insulin-treated patients suffered unplanned multiple surgeries compared with 5.49% (9/164) in the untreated group. A higher percentage of fistula and urinary infections was observed in the untreated group. However, these outcomes were not significantly different between the two groups. Patients in the insulin-treated group had a higher percentage of pneumonia (16.67% [6/36] vs. 6.10% [10/184], P = 0.08) [Figure 1C]. Controlling peri-operative hyperglycemia is necessary for both diabetic and non-diabetic patients because hyperglycemia is associated with a higher incidence of adverse complications.[1] Preventing hyperglycemia should not only be emphasized before and after surgery but intra-operative blood glucose management should also be considered an important part of anesthesiology management. The time points of glucose control should be more active and start as soon as possible.[4] Neutrophils act as the first-line immune cells as they migrate and are recruited to the inflammation site during the initiation stage. Under hyperglycemic conditions, the function of neutrophils is impaired in several aspects. The adhesion and migration molecules expressed on neutrophils are decreased. Thus, they are unable to adhere to the endothelium or migrate to the site of inflammation. Neutrophils release fewer cytokines and prostaglandin under hyperglycemic conditions, which impairs their defense function. Hyperglycemia decreases neutrophil degranulation and bactericidal function.[5] In addition, glycosylated proteins impair the function of neutrophils. These impaired neutrophils have less bactericidal activity, phagocytosis, and production of reactive oxygen species. In an experimental hyperglycemia animal model, the administration of insulin is strongly correlated with the functional improvement of neutrophils. Neutrophils express a number of enzymes that degrade the newly formed wound-healing tissue and prolong the healing process. The process could be restored by insulin and exacerbated by hyperglycemia. Insulin treatment re-established phagocytosis-induced apoptosis in neutrophils and inhibited insulin-degrading enzymes to relieve insulin resistance. Insulin also restored the bactericidal function of neutrophils and ameliorated surgical site infection in mouse models. Our research noted a potential influence of insulin treatment on circulating neutrophil counts. One explanation might be that hyperglycemia triggered more severe pro-inflammatory conditions, so the entire body produced more neutrophils that are intended to migrate to the site of inflammation. The other explanation is that these cells are unable to migrate and be recruited to the inflammation site, so they just circulate in the peripheral blood. In our study, the days of hospitalization after surgery and ICU stay length were longer in patients who received insulin treatment. This paradox could be explained by several reasons. First, these patients have more complications than patients who did not need insulin treatment. Whether intensive intra-operative blood glucose control improved these patients’ outcomes is still unclear. Finally, some diabetes patients already have a very high level of hyperglycemia but have less glucose variability, which means they could adjust to the hyperglycemia conditions. As the number of patients with diabetes and insulin resistance continues to increase, the percentage of patients with perioperative hyperglycemia will continue to rise. A number of papers pointed out that the current guidelines for peri-operative blood glucose control have received little emphasis and are poorly executed. Some researchers have conducted questionnaire research, and one of the concerns is that surgeons and anesthesiologists are unwilling to deal with hyperglycemia because they are worried about hypoglycemia after glucose treatment.[4] Currently, a high level of evidence concerning adequate blood glucose levels only comes from cardiac surgery and patients who were admitted to the ICU. In fact, more surgeries should be analyzed to discover the unique cutoff value for each kind of surgery.[6] Second, intra-operative blood glucose management should be more precise and accurate, with more frequent monitoring of time points, insulin dosage, and arterial blood gas (ABG) levels. There could be some cases that received insulin treatment but were performed with a low standard. Third, glucose variability should also be considered in future studies, as this indicator also has a strong influence on the prognosis of the patient.[7] In summary, this study revealed that in non-cardiac scheduled surgery, patients with intra-operative hyperglycemia treated with insulin had lower absolute counts of neutrophils and WBCs immediately after the surgery and on POD1. This finding indicates the potential influence of insulin treatment on the initiation of post-surgery inflammation. Future studies should focus on specific types of surgery to discover appropriate intra-operative blood glucose targets for the patients. Funding This work was supported by grants from the Education Reform Project Foundation for the Central Universities of Peking Union Medical College (No. 2020zlgc0105), the Training Programme Foundation for Excellent Talents in Dongcheng District of Beijing (No. 2019DCT-M-08), and the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (No. 2019XK320018). Conflicts of interest None.